Second-line treatment cohort:Donafenib tablet, 200 mg BID Po

2 trials

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital

Conditions

Biliary tract cancerHepatocellular carcinoma

Phase 4

Clinical study on the safety and efficacy of donafenib tosylate combined with toripalimab injection in first-line/second-line treatment of patients with advanced biliary tract cancer who refuse chemotherapy

Active, not recruitingChiCTR2100050060

Peking Union Medical College Hospital, Chinese Academy of Medical SciencesBiliary tract cancer

Start: 2021-08-31Updated: 2022-04-25

Safety and efficacy of Donafenib combined with Camrelizumab in primary/second-line treatment of patients with advanced hepatocellular carcinoma

Active, not recruitingChiCTR2100050061

Peking Union Medical College HospitalHepatocellular carcinoma

Start: 2021-08-31Updated: 2022-04-25